Follow this preprint
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers
Navin Venkatraman, Alfred B. Tiono, Georgina Bowyer, Jonathan Powlson, Katharine A. Collins, Sam Coulibaly, Mehreen Datoo, Daniel Silman, Alphonse Ouedraogo, Issa Nébié, Egeruan Imoukhuede, Florian Brod, Pedro Folegatti, Emma Dickinson, Sophie Jamieson, Edith C. Bougouma, Daniel Wright, Duncan Bellamy, Amidou Diarra, Carly M. Bliss, Richard Morter, Greg Glenn, Louis F. Fries, Jenny Reimer, Karin Lovgren-Bengtsson, Megan Baker, Ian Poulton, Sarah Moyle, Eleanor Berrie, Nicola Green, Ekta Mukhopadhyay, Nicola Viebig, Brian Angus, Alison Lawrie, Rachel Roberts, Sarah C. Gilbert, David J.M. Lewis, Sodiomon B. Sirima, Katie J. Ewer, Adrian V. S. Hill
doi: https://doi.org/10.1101/19009282
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Navin Venkatraman
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Alfred B. Tiono
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Georgina Bowyer
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Jonathan Powlson
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Katharine A. Collins
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Sam Coulibaly
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Mehreen Datoo
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Daniel Silman
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Alphonse Ouedraogo
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Issa Nébié
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Egeruan Imoukhuede
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Florian Brod
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Pedro Folegatti
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Emma Dickinson
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Sophie Jamieson
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Edith C. Bougouma
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Daniel Wright
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Duncan Bellamy
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Amidou Diarra
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
Carly M. Bliss
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Richard Morter
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Greg Glenn
4Novavax Inc, 20 Firstfield Road, Gaithersburg, MD 20878, USA
Louis F. Fries
4Novavax Inc, 20 Firstfield Road, Gaithersburg, MD 20878, USA
Jenny Reimer
5Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden
Karin Lovgren-Bengtsson
5Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden
Megan Baker
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Ian Poulton
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Sarah Moyle
3Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, OX3 7JT
Eleanor Berrie
3Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, OX3 7JT
Nicola Green
3Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, OX3 7JT
Ekta Mukhopadhyay
3Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, OX3 7JT
Nicola Viebig
6European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Voßstr. 2, 69115, Germany
Brian Angus
7Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU
Alison Lawrie
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Rachel Roberts
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Sarah C. Gilbert
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
David J.M. Lewis
8NIHR Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Sodiomon B. Sirima
2Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit, Banfora, Burkina Faso
9Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso
Katie J. Ewer
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Adrian V. S. Hill
1Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7DQ, UK
Posted October 18, 2019.
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers
Navin Venkatraman, Alfred B. Tiono, Georgina Bowyer, Jonathan Powlson, Katharine A. Collins, Sam Coulibaly, Mehreen Datoo, Daniel Silman, Alphonse Ouedraogo, Issa Nébié, Egeruan Imoukhuede, Florian Brod, Pedro Folegatti, Emma Dickinson, Sophie Jamieson, Edith C. Bougouma, Daniel Wright, Duncan Bellamy, Amidou Diarra, Carly M. Bliss, Richard Morter, Greg Glenn, Louis F. Fries, Jenny Reimer, Karin Lovgren-Bengtsson, Megan Baker, Ian Poulton, Sarah Moyle, Eleanor Berrie, Nicola Green, Ekta Mukhopadhyay, Nicola Viebig, Brian Angus, Alison Lawrie, Rachel Roberts, Sarah C. Gilbert, David J.M. Lewis, Sodiomon B. Sirima, Katie J. Ewer, Adrian V. S. Hill
medRxiv 19009282; doi: https://doi.org/10.1101/19009282
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (418)
- Allergy and Immunology (740)
- Anesthesia (217)
- Cardiovascular Medicine (3180)
- Dermatology (268)
- Emergency Medicine (469)
- Epidemiology (13156)
- Forensic Medicine (18)
- Gastroenterology (879)
- Genetic and Genomic Medicine (4988)
- Geriatric Medicine (458)
- Health Economics (764)
- Health Informatics (3144)
- Health Policy (1115)
- Hematology (418)
- HIV/AIDS (988)
- Medical Education (463)
- Medical Ethics (122)
- Nephrology (512)
- Neurology (4738)
- Nursing (252)
- Nutrition (701)
- Oncology (2437)
- Ophthalmology (692)
- Orthopedics (272)
- Otolaryngology (335)
- Pain Medicine (316)
- Palliative Medicine (88)
- Pathology (524)
- Pediatrics (1265)
- Primary Care Research (539)
- Public and Global Health (7303)
- Radiology and Imaging (1641)
- Respiratory Medicine (954)
- Rheumatology (468)
- Sports Medicine (411)
- Surgery (528)
- Toxicology (66)
- Transplantation (226)
- Urology (196)